Clinical study

The main goal of the MELISSA project is to test the new MELISSA app that gives people living with diabetes daily, personalized advice on insulin and diabetes management. This testing takes place with the support and close supervision of medical staff.

The study will take place at five clinical sites in four European countries, these are The Netherlands, Denmark, Germany and Greece. The clinical study will include approximately 490 people with type 1 and type 2 diabetes on multiple daily injections of insulin. The total duration of the study will be 22 weeks.

Today, there is no smartphone app with an artificial intelligence-based insulin and carb calculator available for the wider diabetes community. The MELISSA project aims to test how well the app works in people living with diabetes. In the future, approval from European Union health authorities will be sought to enable the app's widespread use in diabetes care.

An overview of the clinical study: Clinical study

What is the MELISSA study about?

The MELISSA app contains an artificial intelligence-based insulin and nutrient calculator – including estimations on calories, carbohydrates, fat and protein – created to assist diabetes self-care. The MELISSA app can be used with a continuous glucose monitor (CGM) or glucose meter, insulin pen and automatic carb counting to provide personalized insulin advice. The MELISSA project strives to improve glucose control, support your diabetes self-care and improve quality of life.

More information will follow soon.

MELISSA app on the phone